Modulating UDP-glucuronosyltransferase activity: Mechanisms, clinical implications, therapeutic strategies, and future directions in drug development.

UDP-glucuronosyltransferases (UGTs) are essential enzymes in the phase II metabolism of endogenous and exogenous compounds, playing a critical role in detoxification, drug metabolism, and clearance. Their function is crucial for the pharmacokinetics of numerous therapeutic agents, but UGT inhibition can result in altered drug metabolism, increased toxicity, or reduced efficacy. This review explores the mechanisms of UGT inhibition, its implications for drug metabolism and pharmacokinetics, and the clinical relevance of such inhibition in the context of drug-drug interactions (DDIs). We discuss the therapeutic strategies targeting UGTs, the impact of environmental and dietary factors on UGT activity, and the role of pharmacogenetics in modulating UGT function. Moreover, the review highlights the role of UGTs in xenobiotic detoxification and addresses the challenges in identifying and modulating UGT inhibition in drug development. Finally, we identify future research directions for understanding UGT inhibition and its clinical applications. By synthesizing recent advances in the field, this review provides a comprehensive overview of the dynamic role of UGTs in drug metabolism, offering insights for optimizing drug therapy and minimizing adverse interactions.

• Publication year

  2025

• Venue

  Enzyme and Microbial Technology

• Publication date

  2025-07-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.enzmictec.2025.110711PMID 40651262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multi-pronged molecular insights into flavonoid-mediated inhibition of squalene epoxidase: a pathway to novel therapeutics

  2025cited by this paper
• Repurposing FDA-approved allosteric drugs as non-competitive inhibitors of human UGTs: An integrated computational study and biochemical validation.

  2025cited by this paper
• Phytochemical inhibitors of squalene epoxidase: Integrated In silico and In vitro mechanistic insights for targeting cholesterol biosynthesis.

  2025cited by this paper
• Mechanism-Based Inhibition of Aldose Reductase by Natural Xanthones: Computational and Experimental Insights for Diabetic Complications

  2025cited by this paper
• A mechanistic experimental and computational exploration of aldose reductase inhibition by coumarins from Ruta chalepensis.

  2025cited by this paper
• Multi-pronged approaches to the mechanism-based inactivation of aldose reductase by natural coumarins: molecular insights and experimental validation

  2025cited by this paper
• Insight into the structure, oligomerization, and the role in drug resistance of human UDP-glucuronosyltransferases

  2025cited by this paper
• Repurposing dual-C-prenylated flavonoids as potent allosteric inhibitors of PTP1B: Integrated phytochemical, enzymological, and in silico evidence.

  2025cited by this paper
• Inhibitory Mechanisms of β‐Glucuronidase by Hibiscus syriacus Phenolics: Integrating Computational and Experimental Approaches

  2025cited by this paper
• Mechanistic Insights into Polyphenols-mediated Squalene Epoxidase Inhibition: Computational Models and Experimental Validation for Targeting Cholesterol Biosynthesis

  2025cited by this paper
• Microbiota governs host chenodeoxycholic acid glucuronidation to ameliorate bile acid disorder induced diarrhea

  2025cited by this paper
• Mechanistic insights into alkaloid-based inhibition of squalene epoxidase: A combined in silico and experimental approach for targeting cholesterol biosynthesis.

  2025cited by this paper
• Mechanisms of intestinal pharmacokinetic natural product-drug interactions

  2024cited by this paper
• Bridging in silico and in vitro perspectives to unravel molecular mechanisms underlying the inhibition of β-glucuronidase by coumarins from Hibiscus trionum.

  2024cited by this paper
• In Vitro Ciclopirox Glucuronidation in Liver Microsomes from Humans and Various Experimental Animals

  2024cited by this paper
• UGT2B10 is the Major UDP-Glucuronosyltransferase 2B Isoform Involved in the Metabolism of Lamotrigine and is Implicated in the Drug-Drug Interaction with Valproic Acid

  2024cited by this paper
• Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: prediction of in vivo drug-drug interactions.

  2024cited by this paper
• Natural products modulate phthalate-associated miRNAs and targets.

  2024cited by this paper
• Unraveling the mechanism of carbonic anhydrase IX inhibition by alkaloids from Ruta chalepensis: A synergistic analysis of in vitro and in silico data.

  2024cited by this paper
• Revolutionizing Drug Discovery: The Impact of Distinct Designs and Biosensor Integration in Microfluidics-Based Organ-on-a-Chip Technology

  2024cited by this paper
• Metabolic Syndrome Drug Therapy: The Potential Interplay of Pharmacogenetics and Pharmacokinetic Interactions in Clinical Practice: A Narrative Review

  2024cited by this paper
• Protein Kinase Inhibitors Indicated for Lung Cancer: Pharmacodynamics, Pharmacokinetics, Adverse Drug Reactions, and Evaluation in Clinical Trials

  2024cited by this paper
• Meta-analysis revisiting the influence of UGT1A1*28 and UGT1A1*6 on irinotecan safety in colorectal cancer patients.

  2024cited by this paper
• Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions

  2024cited by this paper
• Auriculasin induces mitochondrial oxidative stress and drives ferroptosis by inhibiting PI3K/Akt pathway in non-small cell lung cancer

  2024cited by this paper
• Dissecting molecular mechanisms underlying the inhibition of β-glucuronidase by alkaloids from Hibiscus trionum: Integrating in vitro and in silico perspectives

  2024cited by this paper
• Mechanistic insights into the metabolic pathways of vanillin: unraveling cytochrome P450 interaction mechanisms and implications for food safety.

  2024cited by this paper
• Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women

  2024cited by this paper
• Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights

  2024cited by this paper
• Identification of UDP-glucuronosyltransferase (UGT) isoforms involved in the metabolism of Chlorophenols (CPs).

  2024cited by this paper
• Inhibition of Human UDP-Glucuronosyltransferase Enzyme by Entrectinib: Implications for Drug-Drug Interactions.

  2024cited by this paper
• Identification of Bromophenols' glucuronidation and its induction on UDP- glucuronosyltransferases isoforms.

  2024cited by this paper
• Exploring irinotecan adverse reactions in the real world: a study on UGT1A1 heterozygous mutations

  2024cited by this paper
• Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience.

  2024cited by this paper
• Human UDP-glucuronosyltransferase 1As catalyze aristolochic acid D O-glucuronidation to form a lesser nephrotoxic glucuronide.

  2024cited by this paper
• Deciphering the Molecular Mechanisms of Reactive Metabolite Formation in the Mechanism-Based Inactivation of Cytochrome p450 1B1 by 8-Methoxypsoralen and Assessing the Driving Effect of phe268

  2024cited by this paper
• Uridine diphosphate glucuronosyltransferase 1A1 prevents the progression of liver injury

  2024cited by this paper
• mRNA biotherapeutics landscape for rare genetic disorders

  2024cited by this paper
• Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation

  2024cited by this paper
• Acetaminophen Hepatotoxicity: Paradigm for Understanding Mechanisms of Drug-Induced Liver Injury.

  2024cited by this paper
• Inhibition of Uridine 5′-diphospho-glucuronosyltransferases A10 and B7 by vitamins: insights from in silico and in vitro studies

  2024cited by this paper
• A high-affinity fluorescent probe for human uridine-disphosphate glucuronosyltransferase 1A9 function monitoring under environmental pollutant exposure.

  2024cited by this paper
• Exploring the Impact of CYP2D6 and UGT2B7 Gene-Drug Interactions, and CYP-mediated DDI on Oxycodone and Oxymorphone Pharmacokinetics using Physiologically-Based Pharmacokinetic Modelling and Simulation.

  2024cited by this paper
• The Metabolic Characteristics and Bioavailability of Resveratrol Based on Metabolic Enzymes.

  2024cited by this paper
• The Role of UDP-Glycosyltransferases in Xenobiotic Metabolism

  2024cited by this paper
• Integrating Computational Modeling and Experimental Validation to Unveil Tyrosinase Inhibition Mechanisms of Flavonoids from Alhagi graecorum

  2024cited by this paper
• Prediction of Drug-Drug Interactions for Highly Plasma Protein Bound Compounds

  2024cited by this paper
• A UDP-glucuronosyltransferase gene UGT379A1 involved in detoxification of lufenuron in Diaphorina citri.

  2024cited by this paper
• Synergistic and Additive Inhibition of UDP‐Glucuronosyltransferase 1A9 by Endogenous and Foodborne Inhibitors

  2024cited by this paper
• Dynamic interactions and inhibitory mechanisms of Artemisia annua terpenoids with carbonic anhydrase IX.

  2024cited by this paper
• Mechanistic Insights into β-Glucuronidase Inhibition by Isoprenylated Flavonoids from Centaurea scoparia: Bridging Experimental and Computational Approaches

  2024cited by this paper
• Drug-drug interactions of plant alkaloids derived from herbal medicines on the phase II UGT enzymes: an introductory review

  2024cited by this paper
• In Silico Investigation against Inhibitors of Alpha-Amylase Using Structure-based Screening, Molecular Docking, and Molecular Simulations Studies

  2024cited by this paper
• Deciphering molecular mechanisms underlying the inhibition of β-glucuronidase by xanthones from Centaurium spicatum.

  2024cited by this paper
• Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro

  2024cited by this paper
• Glucuronidation of tizoxanide, an active metabolite of nitazoxanide, in liver and small intestine: Species differences in humans, monkeys, dogs, rats, and mice and responsible UDP-glucuronosyltransferase isoforms in humans.

  2024cited by this paper
• In vitro inhibitory effects of selumetinib on activity of human UDP-glucuronosyltransferases and prediction of in vivo drug-drug interactions.

  2024cited by this paper
• Avapritinib Carries the Risk of Drug Interaction via Inhibition of UDP-Glucuronosyltransferase (UGT) 1A1.

  2024cited by this paper
• Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives.

  2024cited by this paper
• A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?

  2023cited by this paper
• Influence of polymorphism of enzymes of the UDP family-glucuronyl transferases on the biotransformation of tamoxifen in the therapy of luminal forms of breast cancer

  2023cited by this paper
• Comparative Intra‐Subject Analysis of Gene Expression and Protein Abundance of Major and Minor Drug Metabolizing Enzymes in Healthy Human Jejunum and Liver

  2023cited by this paper
• A genome-wide association study of 24-hour urinary excretion of endocrine disrupting chemicals.

  2023cited by this paper
• Establishment of UGT1A1-knockout human iPS-derived hepatic organoids for UGT1A1-specific kinetics and toxicity evaluation

  2023cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide

  2023cited by this paper
• The Activity of Members of the UDP-Glucuronosyltransferase Subfamilies UGT1A and UGT2B is Impaired in Patients with Liver Cirrhosis

  2023cited by this paper
• The potential impact of CYP and UGT drug-metabolizing enzymes on brain target site drug exposure

  2023cited by this paper
• Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.

  2023cited by this paper
• Pectolinarigenin ameliorates acetaminophen-induced acute liver injury via attenuating oxidative stress and inflammatory response in Nrf2 and PPARa dependent manners.

  2023cited by this paper
• Nanomaterials for mRNA‐based therapeutics: Challenges and opportunities

  2023cited by this paper
• Lowering glycemic levels via gastrointestinal tract factors: the roles of dietary fiber, polyphenols, and their combination

  2023cited by this paper
• Cabozantinib carries the risk of drug-drug interactions via inhibition of UDP-glucuronosyltransferase (UGT) 1A9.

  2022cited by this paper
• Pharmacokinetic Interactions Between Antiseizure and Psychiatric Medications

  2022cited by this paper
• Discovery and Characterization of the Key Constituents in Ginkgo biloba Leaf Extract With Potent Inhibitory Effects on Human UDP-Glucuronosyltransferase 1A1

  2022cited by this paper
• The Potential Protective Effect and Underlying Mechanisms of Physiological Unconjugated Hyperbilirubinemia Mediated by UGT1A1 Antisense Oligonucleotide Therapy in a Mouse Model of Cyclosporine A-Induced Chronic Kidney Disease

  2022cited by this paper
• Tanshinone I: Pharmacological activities, molecular mechanisms against diseases and future perspectives.

  2022cited by this paper
• Co-exposure health risk of benzo[a]pyrene with aromatic VOCs: Monoaromatic hydrocarbons inhibit the glucuronidation of benzo[a]pyrene.

  2022cited by this paper
• Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

  2022cited by this paper
• Network Analysis of the Herb–Drug Interactions of Citrus Herbs Inspired by the “Grapefruit Juice Effect”

  2022cited by this paper
• The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation

  2022cited by this paper
• Effects of intestinal microbiota on pharmacokinetics of cyclosporine a in rats

  2022cited by this paper
• Potential interactions among myricetin and dietary flavonols through the inhibition of human UDP-glucuronosyltransferase in Vitro.

  2022cited by this paper
• A potential implication of UDP-glucuronosyltransferase 2B10 in the detoxification of drugs used in pediatric hematopoietic stem cell transplantation setting: an in silico investigation

  2022cited by this paper
• The role of UDP-glycosyltransferases in xenobioticresistance

  2022cited by this paper
• Neobavaisoflavone Induces Bilirubin Metabolizing Enzyme UGT1A1 via PPARα and PPARγ

  2021cited by this paper
• Gut microbiota as a target to limit toxic effects of traditional Chinese medicine: Implications for therapy.

  2021cited by this paper
• A fluorescence-based microplate assay for high-throughput screening and evaluation of human UGT inhibitors.

  2021cited by this paper
• Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen

  2021cited by this paper
• Pharmacogenomics in the era of next generation sequencing – from byte to bedside

  2021cited by this paper
• An Efficient Method for the Differentiation of Human iPSC-Derived Endoderm toward Enterocytes and Hepatocytes

  2021cited by this paper
• Novel advances in biotransformation and bioactivation research – 2020 year in review

  2021cited by this paper
• In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions.

  2021cited by this paper
• The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases

  2021cited by this paper
• Intestinal UDP-Glucuronosyltransferase 1A1 and Protection against Irinotecan-Induced Toxicity in a Novel UDP-Glucuronosyltransferase 1A1 Tissue-Specific Humanized Mouse Model

  2021cited by this paper
• The relationship between UGT1A1 gene & various diseases and prevention strategies

  2021cited by this paper
• Targeting gut microbiota for precision medicine: Focusing on the efficacy and toxicity of drugs

  2020cited by this paper
• Inhibition of UDP-glucuronosyltransferases (UGTs) by bromophenols (BPs).

  2020cited by this paper
• An update on drug–drug interactions between antiretroviral therapies and drugs of abuse in HIV systems

  2020cited by this paper
• Dosage Adjustment of Irinotecan in Patients with UGT1A1 Polymorphisms: A Review of Current Literature

  2020cited by this paper
• Gut-on-a-chip: Current progress and future opportunities.

  2020cited by this paper

• No citing papers are available for this paper.